
Verismo Therapeutics licenses in vivo CAR T engineering technology from Stanford Medicine, while Pfizer licenses in vivo CAR-T programs from Starna Therapeutics.
Adding oral L-glutamine to standard chemo nearly tripled median OS in advanced pancreatic cancer — and what comes next.
Jun Gong, MD, associate professor of medicine and medical director of colorectal cancer at Cedars-Sinai, spoke with Pharmaceutical Executive about the results of a Phase I study that researched the impact of adding oral L-glutamine to first-line gemcitabine/nab-paclitaxel in treatment-naïve advanced pancreatic cancer.






